WARF: P160341US02

Rhinovirus-C Peptide for Development of Vaccines and Antivirals


Ann Palmenberg, Marchel Hill, Kelly Watters, Michael Rossman, Yue Liu

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing an immunogenic peptide from rhinovirus-C, as well as related vaccines and therapeutic compounds.
OVERVIEWHuman rhinoviruses (species A, B and C) are responsible for the majority of upper respiratory tract infections (like the common cold) and many infections of the lower respiratory tract as well.

Rhinovirus C species (RV-C) was discovered in 2006 and is of special interest because it can cause more severe illnesses in children and is closely associated with asthma exacerbations. However, no vaccines or effective antiviral treatments for RV-C currently are available.
THE INVENTIONUW–Madison researchers have identified novel immunogenic peptides from RV-C that are useful targets for therapeutic antibodies.

Recent advances in microscopy enabled the researchers to determine (with atomic resolution) the structure of an RV-C strain, both in its full, infectious form and as native empty particles. The structures highlighted immunogenic surfaces that could be used to design antivirals or vaccines against RV-C.
  • Prevention and treatment of RV-C infection, including infection associated with childhood asthma and adult respiratory problems
  • Provides – for the first time – an effective target for vaccines or antivirals against RV-C
For More Information About the Inventors
  • Liu Y., Hill M.G., Klose T., Chen Z., Watters K., Bochkov Y.A., Jiang W., Palmenberg A.C. and Rossmann M.G. 2016. Atomic Structure of a Rhinovirus C, a Virus Species Linked to Severe Childhood Asthma. Proc. Natl. Acad. Sci. USA. 113, 8997-9002.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.